The USPTO recently presented study findings on applications with large patent families, aiming to address public concerns about 'patent thickets' that may harm competition. Conducted over five years, the study highlighted that a significant portion of applications facing double patenting rejections resulted in necessary adjustments such as terminal disclaimers or amendments. This initiative was partly prompted by bipartisan calls from senators who feared that excessive patenting in the pharmaceutical sector restricts competition. The USPTO continues soliciting public input to improve patent integrity and encourage innovation.
Of the applications with identified omitted double patenting rejections, approximately 60% resulted in at least one terminal disclaimer filed and approximately 30% resulted in [an] amendment filed.
Collection
[
|
...
]